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INTRODUCTION
There are widespread neuroendocrine consequences of opioid therapy including hypogonadism and osteoporosis. [1] [2] [3] [4] [5] [6] It can even be said that testosterone serves to maintain health in every system of the body! 7 Opioid induced androgen deficiency can occur after opioids are administered by oral, transdermal, parenteral and intrathecal routes. [8] [9] [10] [11] Opioids reduce androgen production, mainly by suppression of the hypothalamic secretion of gonadotrophin releasing hormone (GRH). Suppression of GRH in turn suppresses the release of luteinising hormone from the pituitary gland, with subsequent effect on the Leydig cells of the testes. 12 There is also a possible direct effect on the testes. 13 This cascade of suppression leads to low levels of testosterone and dihydrotestosterone with subsequent reduction of bone mineral density (BMD) in male patients receiving opioids. 10, 14 We have previously studied patients receiving intrathecal opioids for chronic benign pain both retrospectively 15 and prospectively. 16 We found that they developed hypogonadotrophic hypogonadism. Metabolic sequelae of hypogonadism, such as osteoporosis, were considered at the time but no metabolic bone studies were conducted. Consequently, we have studied male patients who were continuing to receive intrathecal opioids for chronic benign pain for signs of low BMD and altered bone metabolism. In addition, we have studied the effects of supplementary administered testosterone on those patients receiving intrathecal opioids and who were previously diagnosed with opioid induced hypogonadism.
METHODS

After obtaining institutional ethics approval from Murdoch University and Sir
Charles Gairdner Hospital, Perth, Western Australia and informed consent from participating patients, 27 males with chronic benign pain between the ages of 36 to 83 years attending a chronic pain clinic and who had implanted intrathecal pumps (Medtronic Syncromed 11) delivering either morphine sulphate (range 1-20 mg/day, mean 7.2 mg/day) or hydromorphone (range 1-8.5 mg/day, mean 4.15 mg/day) were studied. Other secondary causes of low bone density including thyroid disease, hyperparathyroidism, malabsorption and administered corticosteroids were grounds for patient exclusion from this study. At the time of this study, both serum total and free testosterone levels were higher in patients on supplementary testosterone than in patients who did not receive this treatment (Table) Of the 16 patients not on testosterone supplement, 14 (87%) had low serum testosterone levels (<10 nmol/L) and 11 (69%) had osteopenic (8 patients) or osteoporotic (3 patients) T scores. Within this group, low free testosterone was associated with low BMD scores (Pearson's correlation coefficient = 0.88, p = 0.004), and this persisted after correcting for age (partial correlation coefficient = 0.86, p = 0.014).
Eight of the patients on testosterone supplement had normal BMDT scores and three (27%) had osteopenic T scores. T and age-corrected BMDZ-scores were significantly greater in the 11 patients on testosterone supplements than BMD scores in the other 16 patients (Table) . As well, urinary NTx (an index of bone resorption) was significantly smaller in the testosterone supplement group than in the other patients (Table) . Other measures of bone health (serum alkaline phosphatase, parathyroid hormone and vitamin D levels) were, however, similar in both groups.
DISCUSSION
The results of this small study show that an opioid induced sex hormone endocrinopathy becomes almost universal in patients receiving intrathecal
opioids. This finding is in line with previous studies, including our earlier work, which included prospective data. [15] [16] [17] Opioids administered by any route can induce secondary hypogonadism, and their effects on fertility have been noted in nineteenth and mid twentieth century literature. [18] [19] [20] [21] Although intrathecal opioids provide undisputed benefits for some patients with intractable pain states, they are associated with a number of unwelcome side effects, many of which can be related to hypogonadotrophic hypogonadism. Such side effects include lethargy, depression, loss of libido and sexual function. 10, [22] [23] [24] Metabolic side effects have also been described including the onset of osteoporosis in patients receiving opioids by oral and parenteral routes. 23 Low androgen levels are associated with abnormal bone metabolism, especially in younger males. 10, 23, 25, 26 Androgen deficiency is thought to be an important factor in males suffering hip and vertebral fractures. [27] [28] [29] Gonadal androgens are most probably the principal bone-active steroid hormones in males. 26 Opioids can also have a direct effect on bone metabolism 9, 10 but our patients receiving opioids by the intrathecal route have low serum levels of these drugs. Androgen suppression by opioids via the hypothalamic-pituitary-gonadal axis provides a more logical explanation.
In this study, low free testosterone was associated with low bone density, an effect that persisted after correction for age. These findings replicate our earlier pilot study 30 and a recent study by Duarte et al. of 20 patients receiving intrathecal opioids for chronic benign pain. 31 We have extended this finding to study the effects of supplementary testosterone treatment on BMD. Our data suggest that testosterone supplementation can correct the adverse effects of intrathecal opioids on testosterone levels and BMD. Eight of eleven patients (73%) on testosterone supplement had normal bone density in comparison with low or osteoporotic T scores in eleven of sixteen patients (69%)not on supplement. The beneficial effects of testosterone treatment on BMD in men with testosterone deficiency syndrome have been observed previously and significant effects have been noted at 12 and 24 months. 32 It is reasonable to assume that an improvement in BMD by testosterone treatment can be expected in men rendered hypogonadal by intrathecal opioids. This study provides evidence in support of this assumption. Early monitoring of testosterone and BMD levels in patients recently commenced on intrathecal opioids might even circumvent some of the adverse features of intrathecal opioid therapy. It is unknown how long testosterone supplementation is required for an improvement in BMD to occur as all patients in this study had undergone treatment for more than 2 years and there was no association between duration of treatment and BMD.
A weakness of the study is the low numbers available for the estimation of bone metabolism and androgen levels. We chose to study only male subjects to simplify the hormonal changes expected with aging. Our female patients receiving intrathecal opioids are pre, peri and post-menopausal; however, it is expected this group will also demonstrate significant effects on gonadal hormone secretion and bone density. A profound inhibition of ovarian sex hormone and adrenal androgen can be demonstrated in women chronically consuming sustained action opioids. 33 A further weakness of this study is the lack of BMD data from prior to the commencement of testosterone supplementation. The improvement in BMD levels seen in patients on testosterone supplementation is therefore highly suggestive of cause and effect, but not proven.
In this study, SHBG was higher in untreated patients as a whole than in the group that received testosterone supplements. SHBG is a glycoprotein produced in the liver that is regulated by numerous factors and binds with high affinity to sex hormones, in particular testosterone and oestradiol, regulating their bioavailability. Both of these hormones inhibit osteoporosis in men. 34 Elevated SHBG levels have been associated with osteoporotic fractures in older men and correlate with greater bone loss. 35 SHBG rises with age and cirrhosis of the liver and is reduced with obesity and hypothyroidism. A higher level of SHBG reduces the availability of free testosterone and oestradiol, and is therefore estimated when calculating free testosterone. 36 The estimation of total testosterone may not be as reliable as free testosterone for determining hypogonadism. 37 In a recent study of twenty patients receiving intrathecal opioid, however, no significant differences were observed between the diagnosis of hypogonadism based on total or free testosterone estimation. 38 Testosterone levels can fluctuate widely in normal individuals but are usually higher in the early mornings. The levels can be affected by smoking cigarettes and alcohol consumption, raised Body Mass Index (BMI) and some centrally acting drugs such as anticonvulsants. 23 Surprisingly, benzodiazepines and antidepressants, which are also centrally acting, are not associated with reduced bone density. [39] [40] [41] Many factors other than androgen levels also affect bone metabolism including nutrition and weight bearing exercise. 42 Hypogonadism in its various forms can be countered by androgen supplementation 1, 22, 43, 44 and it is interesting in this study that a large proportion of patients who were receiving testosterone supplement had a normal bone density. It would therefore be reasonable to recommend assessment of testosterone levels and BMD at <6 months from the commencement of intrathecal opioid therapy. Testosterone-depleted patients can present with higher pain scores 45 and administered androgen may even have analgesic effects 46 , providing a further reason for treating the hypogonadism that develops in chronic pain patients receiving intrathecal opioids. Reduction or elimination of opioid treatment is, however, the only reliable method for reducing the metabolic effects of opioid endocrinopathy. Scant attention has been paid to these long-term adverse effects of opioids, particularly on bone density in an aging population. It is perhaps time that this changed.
